Sarah arrived early to review data for a new leukemia drug, LK-203—a compound she had spent three years developing. The therapy combined innovative delivery systems with targeted action and had sparked worldwide excitement. Families desperate for hope enrolled their children in its trials, believing it might be the miracle they needed.

As she logged into her computer, Sarah expected the familiar trial database. Instead, she found an unfamiliar folder labeled “LK-203 Alternative Analysis.” Curious, she opened it. What she saw drained the color from her face.

The files told a different story from the one she had been presenting to the FDA and medical journals. Behind the glossy official reports lay hidden data: alarming rates of liver failure, neurological damage, and immune collapse in the children receiving LK-203. Families had been told side effects were “mild and temporary.” In truth, some children had died. Others were